At the same time, the absence of a harmful signal for other GLP-1 receptor agonists and SGLT2 inhibitors, and the potentially protective association for liraglutide, provide reassurance that these agents can generally be used without substantially increasing intestinal obstruction risk. This evidence concerns the gene SLC5A2 and intestinal obstruction.